{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:36:03Z","timestamp":1777556163351,"version":"3.51.4"},"reference-count":42,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>While evidence supports glycemic control benefits for individuals with type 1 diabetes mellitus (T1DM) using hybrid closed-loop (HCL) systems, HCL automated insulin delivery therapy in China has not been assessed. This study evaluated safety events and effectiveness during HCL system use by Chinese adolescents and adults with T1DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Sixty-two participants (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200912 adolescents with a mean\u2009\u00b1\u2009standard deviation [SD] of 15.5\u2009\u00b1\u20091.1 years and\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200950 adults [mean\u2009\u00b1\u2009SD of 37.6\u2009\u00b1\u200911.1 years]) with T1DM and baseline A1C of 7.1%\u2009\u00b1\u20091.0% underwent a run-in period (\u223c2 weeks) using open-loop Manual Mode (sensor-augmented pump) insulin delivery with the MiniMed\u2122 770G system with the Guardian\u2122 Sensor (3) glucose sensor, followed by a study period (4 weeks) with HCL Auto Mode enabled. Analyses compared continuous glucose monitoring data and insulin delivered during the run-in versus study period (Wilcoxon signed-rank test or\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test). Safety events included rates of severe hypoglycemia and diabetic ketoacidosis (DKA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Compared to baseline run-in, overall Auto Mode use increased time in range (TIR, 70\u2013180\u2009mg\/dL) from 75.3% to 80.9% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and reduced time below range (TBR, &lt;70\u2009mg\/dL) from 4.7% to 2.2% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Subgroup analysis demonstrated that participants (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200929) with baseline A1C &lt;7.0% had TBR that reduced from 5.6% to 2.0%, while participants (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200921) with baseline A1C \u22657.5% had time above range (TAR, &gt;180\u2009mg\/dL) that reduced from 31.6% to 20.8%. Auto Mode use also increased the percentage achieving combined recommendations for time at sensor glucose ranges (i.e., TIR of &gt;70%, TBR of &lt;4% and TAR of &lt;25%) from 24.2% at baseline to 77.4% at study end. Total daily insulin dose reduced from 42.8\u2009\u00b1\u200919.8 to 40.7\u2009\u00b1\u200918.9\u2009U (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.013). There were no severe hypoglycemic, DKA, or serious adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Chinese adolescents and adults, some of whom met target A1C at baseline, safely achieved significantly improved glycemia with 1 month of MiniMed 770G system use when compared to open-loop insulin delivery.\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:uri>\n                      ID: NCT04663295.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2023.0234","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T11:25:27Z","timestamp":1692012327000},"page":"718-725","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus"],"prefix":"10.1177","volume":"25","author":[{"given":"Yu","family":"Pei","sequence":"first","affiliation":[{"name":"Chinese PLA General Hospital, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijian","family":"Ke","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Shanghai General Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai General Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongde","family":"Peng","sequence":"additional","affiliation":[{"name":"Shanghai General Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-7854","authenticated-orcid":false,"given":"Yan","family":"Bi","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3782-9210","authenticated-orcid":false,"given":"Yanbing","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Hou","sequence":"additional","affiliation":[{"name":"Medtronic, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medtronic, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Medtronic, Northridge, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-178X","authenticated-orcid":false,"given":"Yuri","family":"Treminio","sequence":"additional","affiliation":[{"name":"Medtronic, Northridge, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott W.","family":"Lee","sequence":"additional","affiliation":[{"name":"Medtronic, Northridge, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Shin","sequence":"additional","affiliation":[{"name":"Medtronic, Northridge, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Rhinehart","sequence":"additional","affiliation":[{"name":"Medtronic, Northridge, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3546-3385","authenticated-orcid":false,"given":"Robert A.","family":"Vigersky","sequence":"additional","affiliation":[{"name":"Medtronic, Northridge, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Mu","sequence":"additional","affiliation":[{"name":"Chinese PLA General Hospital, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1093"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac022"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2215"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab688"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0310"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0362"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1444"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S014"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S006"},{"key":"e_1_3_5_13_2","first-page":"S1","article-title":"China guideline for type 2 diabetes","volume":"2","author":"Chinese Diabetes Society","year":"2010","unstructured":"Chinese Diabetes Society. China guideline for type 2 diabetes. Chin J Diabetes Mellitus, 2010; 2:S1\u2013S56.","journal-title":"Chin J Diabetes Mellitus"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1177-7"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0026"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1205"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0384"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1406"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12711"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2716"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12962"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0855"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12971"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0421"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11708"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0400"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-020-01607-4"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1447"},{"key":"e_1_3_5_29_2","first-page":"A79","article-title":"Real-world performance of the MiniMed\u2122 780G system: Impact of initiating automated basal and correction boluses","volume":"23","author":"Da Silva J","year":"2021","unstructured":"Da Silva J, , Arrieta A, , Castaneda J, et al. Real-world performance of the MiniMed\u2122 780G system: Impact of initiating automated basal and correction boluses. Diabetes Technol Ther, 2021; 23:A79\u2013A80.","journal-title":"Diabetes Technol Ther"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/19322968221088608"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002633"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2016.0421"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1667"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0264"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13312"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00218-2"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0342"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0782"},{"key":"e_1_3_5_39_2","first-page":"l4894","article-title":"HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study","volume":"366","author":"Lind M","year":"2019","unstructured":"Lind M, , Pivodic A, , Svensson AM, et al. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ (Online), 2019; 366:l4894.","journal-title":"BMJ (Online)"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.05.022"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0040"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1769"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2723"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2023.0234","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2023.0234","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2023.0234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:13:41Z","timestamp":1777400021000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2023.0234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1089\/dia.2023.0234"],"URL":"https:\/\/doi.org\/10.1089\/dia.2023.0234","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}